Prediction of docetaxel response in human breast cancer by gene expression profiling.
暂无分享,去创建一个
Shinzaburo Noguchi | Ryo Matoba | Yasuo Miyoshi | Kyoko Iwao-Koizumi | N. Ueno | Kikuya Kato | Y. Miyoshi | S. Noguchi | R. Matoba | Eisaku Maeda | Seung Jin Kim | Kyoko Iwao-Koizumi | Noriko Ueno | Akiko Ando | Eisaku Maeda | Kikuya Kato | A. Ando | Akiko Ando
[1] P. Schiff,et al. Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[2] G. Powis,et al. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues , 2004, Cancer Chemotherapy and Pharmacology.
[3] Y. Miyoshi,et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer , 2001, International journal of cancer.
[4] J. Yodoi,et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.
[5] L. Walker,et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.
[6] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[7] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[8] H. Bear,et al. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. , 2003, The Surgical clinics of North America.
[9] Nello Cristianini,et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data , 2000, Bioinform..
[10] M. Kavallaris,et al. The role of β-tubulin isotypes in resistance to antimitotic drugs , 2001 .
[11] H. Nakamura,et al. Redox regulation of cellular activation. , 1997, Annual review of immunology.
[12] C. Stein. Mechanisms of action of taxanes in prostate cancer. , 1999, Seminars in oncology.
[13] M. Piccart,et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Yusuke Nakamura,et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.
[15] J. Yodoi,et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. , 1996, The Journal of clinical investigation.
[16] T. Takayama,et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. , 1996, Cancer research.
[17] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[18] S. Ishii,et al. Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data , 2003, Genome Biology.
[19] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[20] Shinzaburo Noguchi,et al. Molecular classification of primary breast tumors possessing distinct prognostic properties. , 2002, Human molecular genetics.
[21] Y. Nakanishi,et al. Immunohistochemical expression of glutathione S‐transferase‐π can predict chemotherapy response in patients with nonsmall cell lung carcinoma , 1996, Cancer.
[22] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[24] Elias S. J. Arnér,et al. Physiological functions of thioredoxin and thioredoxin reductase. , 2000, European journal of biochemistry.
[25] M. Monden,et al. Mutational analysis of the class I β‐tubulin gene in human breast cancer , 2002 .
[26] M. Holland,et al. Transcript Abundance in Yeast Varies over Six Orders of Magnitude* , 2002, The Journal of Biological Chemistry.
[27] J. Blumenstock,et al. Using gene expression ratios to predict outcome among patients with mesothelioma. , 2003, Journal of the National Cancer Institute.
[28] G. Filomeni,et al. Cell signalling and the glutathione redox system. , 2002, Biochemical pharmacology.
[29] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[30] A. Holmgren,et al. Up‐regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma , 2001, International journal of cancer.
[31] B. Trock,et al. Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .
[32] I. Ringel,et al. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.
[33] Kikuya Kato,et al. Adaptor-tagged competitive PCR: a novel method for measuring relative gene expression. , 1997, Nucleic acids research.